pentobarbital will lower the extent or impact of elbasvir/grazoprevir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. The therapeutic outcome of elbasvir/grazoprevir may be minimized if coadministered with potent CYP3A inducers and is particularly as a result contraindicated.pentobarbital will minimize the extent or impac